The study is a statistical analysis of 8 million reports, from 2004 to 2016, from the FDA's Adverse Effect Reporting System database. The full title is, “Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications,” by Dr. R. Abagyan and others, School of Pharmacy, University of California San Diego. It was published in the journal, Nature, on 5/03/2017.
All patients in the study were treated for pain. Those who received ketamine showed decreased depression and pain, compared to those who did not. Side effects of opioid pain relievers were also reduced. Patients who received ketamine needed less opioid medication for pain control.
This is the first study of ketamine to include a very large population of patients. It confirms and reinforces the effectiveness of ketamine for both depression and pain. Previous research trials of ketamine for depression have included fewer patients, usually about 20 – 60 subjects.